Tollip Antibody (k1B17): sc-136152

Tollip Antibody (k1B17) is a mouse monoclonal IgG2a light chain antibody that detects Tollip in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Tollip, or Toll-interacting protein, plays a crucial role in modulating innate immunity by acting as a negative regulator of Toll-like receptor (TLR) signaling pathways. This regulation is vital as it helps to prevent excessive inflammatory responses that can lead to tissue damage during infections. Tollip is primarily located in the cytoplasm and is known to interact with various signaling molecules, including the serine/threonine kinase IRAK, thereby linking Tollip to the IL-1 receptor complex upon receptor activation. This interaction is essential for maintaining a balanced immune response, as Tollip overexpression has been shown to inhibit NFkB activation in response to TLR2 and TLR4 signaling in HEK293 cells. Furthermore, Tollip forms a complex with Tom1, which is important for the endosomal trafficking of ubiquitinated proteins, highlighting Tollip′s role in cellular processes beyond immune regulation. Tollip exhibits ubiquitous expression in mouse tissues, underscoring Tollip′s fundamental importance in various biological contexts. With Tollip′s ability to modulate immune signaling and involvement in protein trafficking, Tollip is a significant target for research in inflammation and immune response.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Tollip Antibody (k1B17) References:

1. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-β signaling pathway.  |  Zhu, L., et al. 2012. J Biol Chem. 287: 39653-63. PMID: 23027871
2. Tollip Negatively Regulates Vascular Smooth Muscle Cell-Mediated Neointima Formation by Suppressing Akt-Dependent Signaling.  |  Zhi, H., et al. 2018. J Am Heart Assoc. 7: PMID: 29887521
3. Tollip Inhibits ST2 Signaling in Airway Epithelial Cells Exposed to Type 2 Cytokines and Rhinovirus.  |  Dakhama, A., et al. 2020. J Innate Immun. 12: 103-115. PMID: 30928973
4. TOLLIP Optimizes Dendritic Cell Maturation to Lipopolysaccharide and Mycobacterium tuberculosis.  |  Venkatasubramanian, S., et al. 2022. J Immunol. 209: 435-445. PMID: 35803695
5. TOLLIP-mediated autophagic degradation pathway links the VCP-TMEM63A-DERL1 signaling axis to triple-negative breast cancer progression.  |  Zhang, TM., et al. 2023. Autophagy. 19: 805-821. PMID: 35920704
6. Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy.  |  Jin, S., et al. 2022. Nat Commun. 13: 5204. PMID: 36057605
7. TOLLIP Protein Expression Predicts Unfavorable Outcome in Renal Cell Carcinoma.  |  Kowalewski, A., et al. 2022. Int J Mol Sci. 23: PMID: 36499030
8. Polymorphisms and haplotypes of TOLLIP and MUC5B are associated with susceptibility and survival in patients with fibrotic hypersensitivity pneumonitis.  |  Mota, PC., et al. 2025. Pulmonology. 31: 2416788. PMID: 38309995
9. Pseudorabies virus UL38 attenuates the cGAS-STING signaling pathway by recruiting Tollip to promote STING for autophagy degradation.  |  Yan, Z., et al. 2024. Virol J. 21: 107. PMID: 38720392
10. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A.  |  Andriani, L., et al. 2024. Cancer Lett. 597: 217008. PMID: 38849012

The preferred Tollip antibody is Tollip Antibody (Kimmy-2): sc-59720.